Januvia · DIN 02388847 · 50 mg · tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Januvia · DIN 02388847
Manufacturer: Merck Frosst Canada Ltd.; listing date 2013-09-27
Health Canada: Marketed since 2012-09-17 · brand JANUVIA · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Merck canada inc · schedule Prescription
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02388847)
Source record
DIN 02388847: Januvia
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id MFC
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $3.4098; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02388847
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87439
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512483 · $0.8197
Apo-Sitagliptin · DIN 02428288 · $0.8197
Apo-Sitagliptin Malate · DIN 02508664 · $0.8197
Auro-Sitagliptin · DIN 02529874 · $0.8197
Jamp Sitagliptin · DIN 02534142 · $0.8197
M-Sitagliptin · DIN 02534991 · $0.8197
Mint-Sitagliptin · DIN 02553929 · $0.8197
NAT-Sitagliptin · DIN 02558165 · $0.8197
PMS-Sitagliptin · DIN 02503859 · $0.8197
PRZ-Sitagliptin · DIN 02545845 · $0.8197
Sandoz Sitagliptin · DIN 02504057 · $0.8197
Sitagliptin · DIN 02529041 · $0.8197
Sitagliptin · DIN 02548569 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197
Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: not checked (no credentials)